Novel biodegradable polymer-coated, paclitaxel-eluting stent inhibits neointimal formation in porcine coronary arteries

Kardiologia Polska

Volumn 68, Issue 5, 2010, Pages 503-509

  Buszman, Paweł ^a,d   Milewski, Krzysztof ^b   Zurakowski, Aleksander ^c   Paja̧k, Jacek ^d   Liszka, Łukasz ^d   Buszman, Piotr ^e   Musioł, Ewa ^d   AbuSamra, Motaz ^f   Trznadel, Stanisław ^a   Kałuza, Grzegorz ^b  

^a American Heart of Poland   (Poland)

^b CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^c Heart and Endovascular Center   (Poland)

^d MEDICAL UNIVERSITY OF SILESIA   (Poland)

^e American Heart of Poland   (Poland)

^f American Heart of Poland   (Poland)

Author keywords

Biodegradable polymer; Drug eluting stents; Neointimal hyperplasia; Porcine

Indexed keywords

PACLITAXEL; POLYMER;

ANGIOCARDIOGRAPHY; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; BARE METAL STENT; CARDIOVASCULAR INFLAMMATION; CONTROLLED STUDY; CORONARY ARTERY; DRUG ELUTING STENT; DRUG INHIBITION; FOLLOW UP; HISTOPATHOLOGY; INTRAVASCULAR ULTRASOUND; MORPHOMETRICS; NONHUMAN; SWINE; ANGIOGENESIS; ANIMAL EXPERIMENT; BIODEGRADABILITY; CORONARY STENT; MATERIAL COATING; NEOINTIMA; SAFETY;

EID: 77953758001     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Stone GW, Moses JW, Ellis SG et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med, 2007; 356: 998-1008.
2. Moses JW, Leon MB, Popma W et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med, 2003; 349: 1315-23.
3. Colombo A, Drzewiecki J, Banning A et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation, 2003; 108: 788-794.
4. Holmes DR Jr., Leon MB, Moses K et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation, 2004; 109: 634-640.
5. Stone GW, Ellis SG, Cox DA et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation, 2004; 109: 1942-1947.
6. Joner M, Finn AV, Farb A et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol, 2006; 48: 193-202.
7. Suzuki T, Kopia G, Hayashi S et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation, 2001; 104: 1188-1193. (Pubitemid 32830406)
8. Drachman DE, Edelman ER, Seifert P et al. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J Am Coll Cardiol, 2000; 36: 2325-2332.
9. Ong AT, McFadden EP, Regar E et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol, 2005; 45: 2088-2092.
10. Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug - eluting stents. JAMA, 2005; 293: 2126-2130.
11. Pfisterer M, Brunner-La Rocca HP, Buser PT et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug - eluting versus bare-metal stents. J Am Coll Cardiol, 2006; 48: 2584-2591.
12. Buszman P, Zurakowski A, Kinasz L et al. The new Polish stent Chopin. Assessment of safety and efficacy in the treatment of de-novo coronary lesions using percutaneous angioplasty. Kardiol Pol, 2005; 62: 451-459.
13. Kornowski R, Hong MK, Tio FO et al. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol, 1998; 31: 224-230.
14. Buszman P, Zurakowski A, Gruszka A et al. Local paclitaxel delivery as a treatment of persistent, recurrent in-stent restenosis: safety assessment. Kardiol Pol, 2006; 64: 268-272.
15. Scheller B, Hehrlein C, Bocksch W et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med, 2006; 355: 2113-2124.
16. Speck U, Scheller B, Abramjuk C et al. Neointima inhibition: comparison of effectiveness of non-stent-based local drug delivery and a drug-eluting stent in porcine coronary arteries. Radiology, 2006; 240: 411-418.
17. Aoki J, Abizaid AC, Serruys PW et al. Evaluation of four-year coronary artery response after sirolimus-eluting stent implantation using serial quantitative intravascular ultrasound and computer-assisted grayscale value analysis for plaque composition in event-free patients. J Am Coll Cardiol, 2005; 46: 1670-1676.
18. Carter AJ, Aggarwal M, Kopia GA et al. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res, 2004; 63: 617-624.
19. Farb A, Heller PF, Shroff S et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation, 2001; 104: 473-479. (Pubitemid 32678280)
20. Scheller B, Grandt A, Wnendt S et al. Comparative study of tacrolimus and paclitaxel stent coating in the porcine coronary model. Z Kardiol, 2005; 94: 445-452.
21. Aragon JK, Tio S, Trauthen F et al. The effect of variable release kinetics on Paclitaxel efficacy from a drug eluting stent in a porcine model. EuroIntervention, 2005; 1: 228-235.
22. Serruys PW, Sianos G, Abizaid A et al. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J Am Coll Cardiol, 2005; 46: 253-260.
23. Daemen J, Ong AT, Stefanini GG et al. Three-year clinical followup of the unrestricted use of sirolimus-eluting stents as part of the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Am J Cardiol, 2006; 98: 895-901.
24. Fajadet J, Morice MC, Bode C et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation, 2005; 111: 1040-1044.
25. Buszman P, Trznadel S, Milewski K et al. Novel paclitaxel-eluting, biodegradable polymer coated stent in the treatment of de novo coronary lesions: a prospective multicenter registry. Catheter Cardiovasc Interv, 2008; 71: 51-57.